Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Full story
Read the full story at CNBC Europe ↗
Continue reading this story on CNBC Europe, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
